Entrada Therapeutics (TRDA) Enterprise Value (2021 - 2026)

Entrada Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$76.4 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 12.69% year-over-year to -$76.4 million; the TTM figure through Mar 2026 stood at -$76.4 million (down 12.69% YoY), while the FY2025 annual figure was -$91.1 million, up 10.04% from the prior year.
• Enterprise Value for Q1 2026 stood at -$76.4 million, up from -$91.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$45.2 million in Q4 2022, with the low at -$263.9 million in Q1 2022.
• The 5-year median for Enterprise Value is -$79.7 million (2023), against an average of -$119.4 million.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value surged 84.49% in 2022, then plunged 132.31% in 2024.
• Entrada Therapeutics' Enterprise Value stood at -$45.2 million in 2022, then slumped by 49.7% to -$67.6 million in 2023, then plunged by 49.72% to -$101.2 million in 2024, then rose by 10.04% to -$91.1 million in 2025, then gained by 16.04% to -$76.4 million in 2026.
• Business Quant data shows TRDA's Enterprise Value at -$76.4 million in Q1 2026, -$91.1 million in Q4 2025, and -$93.3 million in Q3 2025.